Cell cycle and energy metabolism in tumor cells: Strategies for drug therapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 6, Issue 1, 2011, Pages 15-25

  Amoedo, Nivea D ^a   El Bacha, Tatiana ^a   Rodrigues, Mariana F ^a   Rumjanek, Franklin D ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Cancer; CDKs; Cell cycle; Drugs; Metabolism; Reprogramming

Indexed keywords

6 ACETYL 8 CYCLOPENTYL 5 METHYL 2 [5 (1 PIPERAZINYL) 2 PYRIDINYLAMINO] 8H PYRIDO[2,3 D]PYRIMIDIN 7 ONE; ANTINEOPLASTIC AGENT; AT 7519; BROMOPYRUVIC ACID; BUTYRIC ACID; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE 6; CYCLIN DEPENDENT KINASE INHIBITOR; DICHLOROACETIC ACID; DINACICLIB; FLAVOPIRIDOL; HISTONE DEACETYLASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; METFORMIN; N [5 (5 TERT BUTYL 2 OXAZOLYLMETHYLTHIO) 2 THIAZOLYL]ISONIPECOTAMIDE; P 1446A 05; P 27600; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE; PYRUVATE KINASE INHIBITOR; R 547; TRICHOSTATIN A; UNCLASSIFIED DRUG; VALPROIC ACID; VORINOSTAT;

ADJUVANT THERAPY; ADVANCED CANCER; AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LYMPHOMA; BIOENERGY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CARCINOGENESIS; CELL CYCLE REGULATION; CELL METABOLISM; CELL PROLIFERATION; CHROMATIN STRUCTURE; CHRONIC LYMPHATIC LEUKEMIA; DEACETYLATION; DRUG TARGETING; ENDOMETRIUM CANCER; ENERGY METABOLISM; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; GLYCOLYSIS; HEAD AND NECK CANCER; HISTONE ACETYLATION; HUMAN; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; MELANOMA; MULTIPLE MYELOMA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHODGKIN LYMPHOMA; NONHUMAN; OXIDATION REDUCTION STATE; OXIDATIVE STRESS; PRIORITY JOURNAL; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; SKIN LYMPHOMA; SOLID TUMOR; T CELL LYMPHOMA;

EID: 78650936100     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489211793980006     Document Type: Article

References (81)

1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human genome. Science 2002; 298(5600): 1912-34.
2. Lavecchia A, Di Giovanni C, Novellino E. CDC25A and B dual-specificity phosphatase inhibitors: Potential agents for cancer therapy. Curr Med Chem 2009; 16(15): 1831-49.
3. Davidson G, Niehrs C. Emerging links between CDK cell cycle regulators and Wnt signaling. Trends Cell Biol 2010; 20(8): 453-60.
4. Kojima K, Shimanuki M, Shikami M, Andreeff M, Nakakuma H. Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53- mediated Bax activation and mitochondrial apoptosis in AML. Cancer Sci 2009; 100(6): 1128-36.
5. Krystof V, Uldrijan S. Cyclin-dependent kinase inhibitors as anticancer drugs. Curr Drug Targets 2010; 11(3): 291-302.
6. Mason EF, Rathmell JC. Cell metabolism: An essential link between cell growth and apoptosis. Biochim Biophys Acta 2010, (in press) doi:10.1016/j.bbamcr.2010.08.011.
7. Ralph SJ, Rodriguez-Enriquez S, Neuzil J, Saavedra E, Moreno Sanchez R. The causes of cancer revisited: Mitochondrial malignancy and ROS-induced oncogenic transformation - why mitochondria are targets for cancer therapy. Mol Aspects Med 2010; 31(2): 145-70.
8. Reuter S, Gupta SC, Chaturvedi MM, Aggarwal BB. Oxidative stress, inflammation, and cancer: How are they linked? Free Radic Biol Med 2010, (in press) doi:10.1016/j.freeradbiomed.2010. 09.006.
9. Tong X, Zhao F, Mancuso A, Gruber JJ, Thompson CB. The glucose-responsive transcription factor ChREBP contributes to glucose-dependent anabolic synthesis and cell proliferation. Proc Natl Acad Sci USA 2009; 106(51): 21660-5.
10. Sherr CJ. Tumor surveillance via the ARF-p53 pathway. Genes Dev 1998; 12(19): 2984-91.
11. Akritopoulou-Zanze I, Hajduk PJ. Kinase-targeted libraries: The design and synthesis of novel, potent, and selective kinase inhibitors. Drug Discov Today 2009; 14(5-6): 291-7.
12. Echalier A, Endicott JA, Noble ME. Recent developments in cyclin-dependent kinase biochemical and structural studies. Biochim Biophys Acta 2010; 1804(3): 511-9.
13. Hochegger H, Takeda S, Hunt T. Cyclin-dependent kinases and cell-cycle transitions: Does one fit all? Nat Rev Mol Cell Biol 2008; 9(11): 910-6.
14. Murray AW. Recycling the cell cycle: Cyclins revisited. Cell 2004; 116(2): 221-34.
15. Errico A, Deshmukh K, Tanaka Y, Pozniakovsky A, Hunt T. Identification of substrates for cyclin dependent kinases. Adv Enzyme Regul 2010; 50(1): 375-99.
16. Hayward NK. Genetics of melanoma predisposition. Oncogene 2003; 22(20): 3053-62.
17. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: A changing paradigm. Nat Rev Cancer 2009; 9(3): 153-66.
18. Blain SW. Switching cyclin D-CDK4 kinase activity on and off. Cell Cycle 2008; 7(7): 892-8.
19. Kim JK, Diehl JA. Nuclear cyclin D1: An oncogenic driver in human cancer. J Cell Physiol 2009; 220(2): 292-6.
20. Johnson LN. The regulation of protein phosphorylation. Biochem Soc Trans 2009; 37(Pt 4): 627-41.
21. Knight ZA, Lin H, Shokat KM. Targeting the cancer kinome through polypharmacology. Nat Rev Cancer 2010; 10(2): 130-7.
22. Raucher D, Moktan S, Massodi I, Bidwell GL, 3rd. Therapeutic peptides for cancer therapy. Part II cell cycle inhibitory peptides and apoptosis-inducing peptides. Expert Opin Drug Deliv 2009; 6(10): 1049-64.
23. Cantrell LA, Zhou C, Mendivil A, Malloy KM, Gehrig PA, Bae Jump VL. Metformin is a potent inhibitor of endometrial cancer cell proliferation-implications for a novel treatment strategy. Gynecol Oncol 2010; 116(1): 92-8.
24. Grenader T, Goldberg A, Shavit L. Metformin as an addition to conventional chemotherapy in breast cancer. J Clin Oncol 2009; 27(35): e259; author reply e60.
25. Memmott RM, Dennis PA. LKB1 and mammalian target of rapamycin as predictive factors for the anticancer efficacy of metformin. J Clin Oncol 2009; 27(34): e226; author reply e7.
26. Bellance N, Lestienne P, Rossignol R. Mitochondria: From bioenergetics to the metabolic regulation of carcinogenesis. Front Biosci 2009; 14: 4015-34.
27. Kroemer G, Pouyssegur J. Tumor cell metabolism: Cancer's Achilles' heel. Cancer Cell 2008; 13(6): 472-82.
28. Wu M, Neilson A, Swift AL, Moran R, Tamagnine J, Parslow D, et al. Multiparameter metabolic analysis reveals a close link between attenuated mitochondrial bioenergetic function and enhanced glycolysis dependency in human tumor cells. Am J Physiol Cell Physiol 2007; 292(1): C125-36.
29. Warburg O. On respiratory impairment in cancer cells. Science 1956; 124(3215): 269-70.
30. Guppy M, Leedman P, Zu X, Russell V. Contribution by different fuels and metabolic pathways to the total ATP turnover of proliferating MCF-7 breast cancer cells. Biochem J 2002; 364 (Pt 1): 309-15.
31. Zu XL, Guppy M. Cancer metabolism: Facts, fantasy, and fiction. Biochem Biophys Res Commun 2004; 313(3): 459-65.
32. Costello LC, Franklin RB. Tumor cell metabolism: The marriage of molecular genetics and proteomics with cellular intermediary metabolism; proceed with caution! Mol Cancer 2006; 5: 59.
33. Ralph SJ, Low P, Dong L, Lawen A, Neuzil J. Mitocans: Mitochondrial targeted anti-cancer drugs as improved therapies and related patent documents. Recent Pat Anticancer Drug Discov 2006; 1(3): 327-46.
34. Takai N, Kawamata N, Gui D, Said JW, Miyakawa I, Koeffler HP. Human ovarian carcinoma cells: Histone deacetylase inhibitors exhibit antiproliferative activity and potently induce apoptosis. Cancer 2004; 101(12): 2760-70.
35. Mathupala SP, Ko YH, Pedersen PL. Hexokinase-2 bound to mitochondria: Cancer's stygian link to the Warburg Effect and a pivotal target for effective therapy. Semin Cancer Biol 2009; 19(1): 17-24.
36. Pouyssegur J, Dayan F, Mazure NM. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 2006; 441(7092): 437-43.
37. Gatenby RA, Gillies RJ. Why do cancers have high aerobic glycolysis? Nat Rev Cancer 2004; 4(11): 891-9.
38. Swietach P, Vaughan-Jones RD, Harris AL. Regulation of tumor pH and the role of carbonic anhydrase 9. Cancer Metastasis Rev 2007; 26(2): 299-310.
39. Taylor CT, Pouyssegur J. Oxygen, hypoxia, and stress. Ann N Y Acad Sci 2007; 1113: 87-94.
40. Ralph SJ, Neuzil J. Mitochondria as targets for cancer therapy. Mol Nutr Food Res 2009; 53(1): 9-28.
41. Bellance N, Benard G, Furt F, Begueret H, Smolkova K, Passerieux E, et al. Bioenergetics of lung tumors: Slteration of mitochondrial biogenesis and respiratory capacity. Int J Biochem Cell Biol 2009; 41(12): 2566-77.
42. Arismendi-Morillo G. Electron microscopy morphology of the mitochondrial network in human cancer. Int J Biochem Cell Biol 2009; 41(10): 2062-8.
43. Ishikawa K, Takenaga K, Akimoto M, Koshikawa N, Yamaguchi A, Imanishi H, et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 2008; 320(5876): 661-4.
44. Simonnet H, Alazard N, Pfeiffer K, Gallou C, Beroud C, Demont J, et al. Low mitochondrial respiratory chain content correlates with tumor aggressiveness in renal cell carcinoma. Carcinogenesis 2002; 23(5): 759-68.
45. + channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell 2007; 11(1): 37-51.
46. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: A metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006; 3(3): 177-85.
47. Bustamante E, Morris HP, Pedersen PL. Energy metabolism of tumor cells. Requirement for a form of hexokinase with a propensity for mitochondrial binding. J Biol Chem 1981; 256(16): 8699-704.
48. Pastorino JG, Hoek JB. Regulation of hexokinase binding to VDAC. J Bioenerg Biomembr 2008; 40(3): 171-82.
49. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria. Oncogene 2006; 25(34): 4777-86.
50. Gottlob K, Majewski N, Kennedy S, Kandel E, Robey RB, Hay N. Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. Genes Dev 2001; 15(11): 1406-18.
51. Chang GG, Hsu RY. Mechanism of pigeon liver malic enzyme: Kinetics, specificity, and half-site stoichiometry of the alkylation of a cysteinyl residue by the substrate-inhibitor bromopyruvate. Biochemistry 1977; 16(2): 311-20.
52. Korotchkina LG, Ali SM, Patel MS. Involvement of alpha-cysteine-62 and beta-tryptophan-135 in human pyruvate dehydrogenase catalysis. Arch Biochem Biophys 1999; 369(2): 277-87.
53. Tunnicliff G, Ngo TT. Mechanism of inactivation of brain glutamic decarboxylase by 3-bromopyruvate. Int J Biochem 1978; 9(4): 249-52.
54. Ko YH, Smith BL, Wang Y, Pomper MG, Rini DA, Torbenson MS, et al. Advanced cancers: Eradication in all cases using 3- bromopyruvate therapy to deplete ATP. Biochem Biophys Res Commun 2004; 324(1): 269-75.
55. Pereira da Silva AP, El-Bacha T, Kyaw N, dos Santos RS, da-Silva WS, Almeida FC, et al. Inhibition of energy-producing pathways of HepG2 cells by 3-bromopyruvate. Biochem J 2009; 417(3): 717-26.
56. Ko, Y.H.G., Jean-francois, H., Pedersen, P.L. Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production. US7547673 (2009).
57. Ko, Y.H.G. Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production. US20100221220 (2010)
58. Thangaraju M, Karunakaran SK, Itagaki S, Gopal E, Elangovan S, Prasad PD, et al. Transport by SLC5A8 with subsequent inhibition of histone deacetylase 1 (HDAC1) and HDAC3 underlies the antitumor activity of 3-bromopyruvate. Cancer 2009; 115(20): 4655-66.
59. Brian, R., Smith, T.-H.C., Brian, L.-J. Novel inhibitors of pyruvate kinase as therapeutic agents for cancer. US20080311183 (2008).
60. Donald, J., Abraham, C.W., Richmond, D.-D., James, C. Burnett, G. S., Joshi, S. J. H. Allosteric inhibitors of pyruvate kinase. US6534501 (2003).
61. Evangelos, M., Stephen, A. Method of treating cancer using dichloroacetate. US20090118370 (2009).
62. Gu W, Roeder RG. Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. Cell 1997; 90(4): 595-606.
63. Witt O, Deubzer HE, Milde T, Oehme I. HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277(1): 8-21.
64. Xie H, Bandhakavi S, Roe MR, Griffin TJ. Preparative peptide isoelectric focusing as a tool for improving the identification of lysine-acetylated peptides from complex mixtures. J Proteome Res 2007; 6(5): 2019-26.
65. Aoyagi S, Archer TK. Modulating molecular chaperone Hsp90 functions through reversible acetylation. Trends Cell Biol 2005; 15(11): 565-7.
66. Quivy V, Van Lint C. Regulation at multiple levels of NF-kappaB- mediated transactivation by protein acetylation. Biochem Pharmacol 2004; 68(6): 1221-9.
67. Roy S, Packman K, Jeffrey R, Tenniswood M. Histone deacetylase inhibitors differentially stabilize acetylated p53 and induce cell cycle arrest or apoptosis in prostate cancer cells. Cell Death Differ 2005; 12(5): 482-91.
68. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, et al. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst 2002; 94(7): 504-13.
69. FDA approval and New Drug Application (NDA) documents for ZolinzaTM (SAHA,vorinostat)Availablefrom:http://www.accessdata.fda.gov/dr ugsatfda_docs/nda/2006/021991s000_ZolinzaTOC.cfm
70. Wang H, Dymock, BW. New patented histone deacetylase inhibitors. Expert Opin Ther Pat 2009; 19(12): 1727-57.
71. Ungerstedt JS, Sowa Y, Xu WS, Shao Y, Dokmanovic M, Perez G, et al. Role of thioredoxin in the response of normal and transformed cells to histone deacetylase inhibitors. Proc Natl Acad Sci USA 2005; 102(3): 673-8.
72. Wojtczak L, Teplova VV, Bogucka K, Czyz A, Makowska A, Wieckowski MR, et al. Effect of glucose and deoxyglucose on the redistribution of calcium in ehrlich ascites tumour and Zajdela hepatoma cells and its consequences for mitochondrial energetics. Further arguments for the role of Ca(2+) in the mechanism of the crabtree effect. Eur J Biochem 1999; 263(2): 495-501.
73. Gogvadze V, Orrenius S, Zhivotovsky B. Mitochondria in cancer cells: What is so special about them? Trends Cell Biol 2008; 18(4): 165-73.
74. Kallio A, Zheng A, Dahllund J, Heiskanen KM, Harkonen P. Role of mitochondria in tamoxifen-induced rapid death of MCF-7 breast cancer cells. Apoptosis 2005; 10(6): 1395-410.
75. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, et al. Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 2001; 15(9): 1613-5.
76. Ponchaut S, van Hoof F, Veitch K. Cytochrome aa3 depletion is the cause of the deficient mitochondrial respiration induced by chronic valproate administration. Biochem Pharmacol 1992; 43(3): 644-7.
77. Silva MF, Ruiter JP, Ijlst L, Jakobs C, Duran M, de Almeida IT, et al. Differential effect of valproate and its Delta2- and Delta4- unsaturated metabolites, on the beta-oxidation rate of long-chain and medium-chain fatty acids. Chem Biol Interact 2001; 137(3): 203-12.
78. Turnbull DM, Bone AJ, Bartlett K, Koundakjian PP, Sherratt HS. The effects of valproate on intermediary metabolism in isolated rat hepatocytes and intact rats. Biochem Pharmacol 1983; 32(12): 1887-92.
79. Leschelle X, Delpal S, Goubern M, Blottiere HM, Blachier F. Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur J Biochem 2000; 267(21): 6435-42.
80. Boren J, Lee WN, Bassilian S, Centelles JJ, Lim S, Ahmed S, et al. The stable isotope-based dynamic metabolic profile of butyrate-induced HT29 cell differentiation. J Biol Chem 2003; 278(31): 28395-402.
81. Wardell SE, Ilkayeva OR, Wieman HL, Frigo DE, Rathmell JC, Newgard CB, et al. Glucose metabolism as a target of histone deacetylase inhibitors. Mol Endocrinol 2009; 23(3): 388-401.